Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-03-22
2011-03-22
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S193100, C514S002600, C530S326000
Reexamination Certificate
active
07910109
ABSTRACT:
There is provided an MHC class II peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the minimal epitope from the amino acid sequence shown as SEQ ID No. 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 3; (iii) a minimal epitope from the region 281-420 of 5T4. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.
REFERENCES:
patent: 4558035 (1985-12-01), Johnson
patent: 5118672 (1992-06-01), Schinazi et al.
patent: 5356779 (1994-10-01), Mozes et al.
patent: 5869053 (1999-02-01), Stern et al.
patent: 0110385 (1984-06-01), None
patent: 0198328 (1986-10-01), None
patent: 1152060 (2001-11-01), None
patent: 2370571 (2002-07-01), None
patent: WO89/07947 (1989-09-01), None
patent: WO98/03568 (1992-03-01), None
patent: WO97/19183 (1997-05-01), None
patent: WO99/15683 (1999-04-01), None
patent: WO99/15684 (1999-04-01), None
patent: WO 00/29428 (2000-05-01), None
patent: WO 01/00225 (2001-01-01), None
Bodey, B et al. Anticancer Research [2000] 20:2665-2676.
Marchand, M et al. Int. J. Cancer [1999] 20:219-230.
Marchand, M et al. Exp. Opin. Biol. Ther. [2001] 1(3):497-510.
Myers et al (J. Biol. Chem. 269:9319-9324, 1994).
Farrar and Schrieber (Ann. Rev. Immunol. 1993, p. 580).
Guschlbauer, et al. “Poly-2′-deoxy-2′-fluoro-cytidylic acid: enzymatic synthesis, spectroscopic characterization and interaction with poly-inosinic acid”,Nucleic Acids Res.(1997) 4:1933.
Schibahara, et al. “Site-directed cleavage of RNA”,Nucleic Acids Res.(1987) 15:4403.
Gershon, et al. “The nucleotide sequence around the capripoxvirus thymidine kinase gene reveals a shared specifically with leporipoxvirus”,J. Gen. Virol,(1989) 70:525.
Weir, et al. “Nucleotide sequence of the vaccinia virus thymidine kinase gene and the nature of spontaneous frameshift mutations”,J. Virol.(1983) 46:530.
Esposito, et al. “Nucleotide sequence of the thymidine kinase gene region of monkeypox and variola viruses”,Virology(1984) 135:561.
Kilpatrick, et al. “Cloning and physical mapping of yada monkey tumor virus DNA”Virology(1985) 143:399.
Binns, et al. “Comparison of a conserved region in fowlpox virus and caccinia virus gnomes and the translocation of the fowlpox virus thymidine kinase gene”,J. Gen Virol(1988) 69:1275.
Schnitzlein, et al. “A rapid method for identifying the thymidine kinase genes of avipoxviruses”,J. Virological Method(1988) 23:341.
Fathi, et al. “Efficient targeted insertion of an unselected marker into the vaccinia virus genome”,Virology(1986) 97:105.
Graham, et al. “A new technique for the assay of infectivity of human adenovirus 5 DNA”,Virol.(1973) 52:456-467.
Straubinger, et al. “Liposomes as carriers of intracellular delivery of nucleic acids”,Methods in Enzymology,(1983) 101:512-527.
Studier, et al. “Use of T7 RNA polymerase to direct expression of cloned genes”,Methods in Enzymol.(1990) 185:60-89.
Matthias, et al. “Eukaryotic expression vectors for the analysis of mutant proteins”,NAR(1989) 17:6418.
Wootton & Federhen, “Statistics of local complexity in amino acid sequences and sequence databases”,Computers and Chemistry(1993) 17:149-163.
Myers, et al. “Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein”,J. Biol. Chem.(1994) 169:9319-9324.
Starzynska, et al. “The expression of 5T4 antigen in colorectal and gastic carcinoma”,Br. J. Cancer(1992) 66(5):867-869.
Starzynska, et al. “Prognostic significance of 5T4 oncofetal antigen expression in colorectal”Br. J. Cancer(1994) 69(5):899-902.
Hobbs, et al. “Polynucleotides containing 2′-amino-2′-deoxyribose and 2′azido-2′-deoxyribose”,Biochemistry(1973) 12:5138.
Starzynska, et al. “5T4 oncofetal antigen in gastric carcinoma and its clinical significance”,Eur J. Gastroenterol Hepatol(1998) 10(6)479-484.
Carsberg, et al. “Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motilityin epithelial cells”,Int. J. Cancer(1996) 68(1):84-92.
Yewdell, et al. “TAP-independent delivery of antigenic peptides to the endoplasmic reticulum: therapeutic potential and insights into TAP-dependent antigen processing”,J. Immunotherapy(1998) 21:127-31.
Calvert, et al. “Fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus induce neutralizing antibodies and reduce viremia in chickens”,J. of Virol.(1993) 67:3069-3076.
Carroll, et al. “Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen”,J. Natl. Cancer Inst.(1998) 90(24):1881-1887.
Carroll, et al. “Two bright new faces in gene therapy”,Nature Biotechnology(1996) 14:556.
Pieken, et al. “Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes”,Science(1991) 253:314-317.
Parker, et al. “Scheme for ranking potential HLA-A2 binding peptides based on indpendent binding of individual peptide side-chains”,J. Immunol.(1994) 152:163-175.
Fu, et al. “An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope”,J. Virol.(1998) 72:1469-81.
Schödel, et al. “Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety”,Intervirology(1996) 39:104-10.
Wolff and Trubetskoy “The cambrian period of nonviral gene delivery”,Nature Biotechnology(1998), 16:421-423.
Taylor, et al. “Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species”,Vaccine(1998) 79:1637-46.
Stannard, et al. “Evidence for incomplete replication of a penquin poxvirus in cells of mammalian origin”,J. Gen. Virol.(1998) 79:1637-46.
Mackett, et al. “Vaccinia virus: a selectable eukaryotic cloning and expression vector”,PNAS(1982) 79:7415-7419.
Upton, et al. “Identification and nucleotide sequence of the thymidine kinase gene of shope fibroma virus”,J. Virology(1986) 60:920.
Boyle, et al. “Fowlpox virus thymidine kinase: nucleotide sequence and relationships to other thymidine kinase”,Virology(1987) 156:355-365.
Lewis, et al. “Human immunodeficiency virus infection of cells arrested in the cell cycle”EMBO J.(1992) 11:3053-3058.
Lewis and Emerman, “Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus”,J. Virol.(1994) 68:510-516.
Mackett, et al. “General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes”,J. Viral.(1984) 49:857-864.
Hruby, et al. “Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene”,PNAS(1983) 80:3411-3415.
Lytvyn, et al. “Comparison of the thymidine dinase genes from three entompoxiruses”,J. Gen Viral,(1992) 73:3235-3240.
Smith, et al. “Vaccinia virus immune evasion”,Immunol Rev.(1997) 159:137-154.
Jenkins, et al. “Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus”,AIDS Research and Human Retroviruses(1991) 7:991-998.
Taylor, et al. “Recombinant fowlpox virus inducing protective immunity in non-avian species”,Vaccine(1988) 6:497-503.
Sphener, et al. “Insertion of the fusion gene from Newcastle disease virus into a non-essential region in the terminal repeats of fowlpox virus and demonstration of protective immunity induced by the recombinant”,J.
Carroll Miles
Harrop Richard
Kingsman Susan
DiBrino Marianne
Marshall & Gerstein & Borun LLP
Oxford Biomedica (UK) Ltd.
Szperka Michael
LandOfFree
MHC class II epitopes of 5T4 antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MHC class II epitopes of 5T4 antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MHC class II epitopes of 5T4 antigen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2685841